{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:40:06Z","timestamp":1751370006862,"version":"3.41.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/14712598.2025.2517853","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T22:34:51Z","timestamp":1749508491000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma"],"prefix":"10.1080","volume":"25","author":[{"given":"Amrita","family":"Goyal","sequence":"first","affiliation":[{"name":"University of Minnesota","place":["Minneapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine","place":["New Haven"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588236"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.712"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26760"},{"key":"e_1_3_5_8_1","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): primary cutaneous lymphomas, version 1","author":"National Comprehenisve Cancer Network","year":"2024","unstructured":"National Comprehenisve Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): primary cutaneous lymphomas, version 1. 2024. h ttps:\/\/d oi.org\/www.NCCN.org"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17117"},{"key":"e_1_3_5_10_1","unstructured":"FDA. Ontak label."},{"key":"e_1_3_5_11_1","unstructured":"Denileukin diftitox - product approval information - licensing action. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1999\/denser020599L.htm"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13513"},{"key":"e_1_3_5_13_1","unstructured":"FDA. Lymphir Label."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-456988"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2000.s.005"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.2.612"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.5.1.33"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S5009"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)50310-6"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.706286"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25947"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268979"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14906"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01549"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2001.n.005"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.059"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.720372"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21180"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701268783"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701843254"},{"issue":"2","key":"e_1_3_5_33_1","first-page":"399","article-title":"Phase I trial of a ligand fusion-protein (DAB389IL\u20132) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre CF","year":"1998","unstructured":"LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL\u20132) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91(2):399\u2013405.","journal-title":"Blood"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008241"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.742521"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2517853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:15:22Z","timestamp":1751368522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2517853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/14712598.2025.2517853"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2517853","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}